Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.
D000293:Adolescent; D000328:Adult; D001714:Bipolar Disorder / Q000175:diagnosis; D001923:Brain Chemistry / Q000187:drug effects; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010288:Parenteral Nutrition; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012075:Remission, Spontaneous; D012559:Schizophrenia / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D012565:Schizophrenic Psychology
D010919:Placebos; D008774:Methylphenidate; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine